The Hollow-Fibre Infection Model (HFIM)
The Hollow Fibre Infection Model (HFIM) provides a closed system where organisms can be exposed to repeated fluctuating antimicrobial concentrations replicating those seen in vivo. It can be used for dose ranging, drug combination testing and investigating the dynamics of resistance development or suppression with repeated administrations. HFIM offers experimental design including pharmacokinetic simulations, preliminary Minimum Inhibitory Concentration (MIC), synergy and time kill testing. The Hollow-Fibre Infection Model represents significant advantages over standard static methods. This innovative approach simulates the dynamic conditions of microbial infections within the human body, providing a more realistic and informative assessment of antimicrobial activity. Here are some key advantages of the Hollow-Fibre Infection Model: Mimicking In Vivo Conditions: Unlike traditional static methods, the Hollow-Fibre Infection Model replicates the complexity of in vivo infection scenarios. It considers factors such as drug diffusion, host-pathogen interactions, and pharmacokinetic properties. This dynamic simulation provides a more accurate representation of how antimicrobial agents perform within the human body.     Assessing Drug Efficacy Over Time: The dynamic nature of the Hollow-Fibre Infection Model allows for longitudinal assessment of drug efficacy. It enables tracking of antimicrobial activity against microorganisms over extended periods, providing valuable insights into the durability and potential development of resistance. This information is critical for optimizing treatment strategies and combating antimicrobial resistance. Enhancing Drug Development: The Hollow-Fibre Infection Model is a valuable tool in the drug development process. It aids in the preclinical evaluation of antimicrobial candidates, providing critical data on drug potency, dosing, and potential resistance. This information can guide further optimization and streamline the path to successful clinical trials. By harnessing the power of the Hollow-Fibre Infection Model, we can unlock deeper insights into antimicrobial activity, optimize treatment strategies, and shape the future of infectious disease management. At the Antimicrobial PK/PD Laboratory (APPL), we are at the forefront of this revolutionary approach, offering comprehensive testing services that leverage the advantages of the Hollow-Fibre Infection Model. Contact us today to explore how our expertise in this cutting-edge model can elevate your antimicrobial research and support your pursuit of effective treatments. Together, we can combat infectious diseases and improve patient outcomes with a more precise and realistic understanding of antimicrobial activity.

Contact Us

---

Antimicrobial Pharmacokinetic Pharmacodynamic Laboratory UCL Great Ormond Street Institute of Child Health 30 Guilford Street London WC1N 1EH Email: mail@antimicrobialpkpdlab.co.uk hfim@ucl.ac.uk